correlated with increased plasma homocysteine levels. 4 Nitrous oxide exposure has also been associated with an increased incidence of delayed ischaemic neurological deficits reported in a non-randomized secondary analysis of the Intraoperative Hypothermia in Aneurysm Surgery Trial. 5 While controversial, these findings suggest that nitrous oxide may increase vulnerability to ischaemic injury. As nitrous oxide inhibits methionine synthase function leading to the generation of homocysteine, 6 potentially leading to endothelial dysfunction and vasospasm, 7 this hypothesis is plausible. Furthermore, unlike other volatile inhaled anaesthetics, nitrous oxide lacks neuroprotective 6 8 or preconditioning 9 10 effects. Nitrous oxide has also been implicated in neurotoxicity, although any effects in this context appear mild. 6 We performed a secondary analysis of patients who received general anaesthesia (GA) in the General Anaesthesia versus Local Anaesthesia for carotid surgery (GALA) trial 11 to help determine whether intraoperative nitrous oxide exposure was associated with an increased risk of perioperative stroke, myocardial infarction, and death in this large cohort of patients.
Methods
The GALA trial methodology is available elsewhere. 11 12 The trial was registered with Current Control Trials, number ISRCTN00525237. In brief, 3256 eligible patients were randomized to GA or local anaesthesia for carotid surgery. This secondary analysis included patients who actually received GA during the trial, regardless of group allocation creating a cohort of 1773 patients undergoing GA (1629 patients allocated to GA and 144 randomized to local anaesthesia but given GA). Patients in whom nitrous oxide exposure (yes/no) was not recorded were excluded from the analysis. The administration of nitrous oxide was not randomized but rather left to the discretion of the anaesthetist. The inspired nitrous oxide concentration was not recorded on the trial data sheet and so the dose of the drug is unknown. To reduce any sort of expectation bias from this secondary analysis, the primary and secondary outcome measures were not altered from the original trial protocol. The primary outcome was the risk of death, stroke, or myocardial infarction within 30 days of the operation. Secondary outcomes included the risk of stroke and risk of death from stroke.
The P-values presented in the patient characteristic tables were calculated excluding those patients where the nitrous oxide status was unknown (i.e. the comparison was definitely nitrous oxide vs definitely no nitrous oxide). Where the variables of interest were categorical, they were calculated using the binomial test for comparison of proportions (variables containing two levels) and x 2 tests (where there were more than two levels). For the continuous variables, a two-sample t-test was used to examine the differences between those who received nitrous oxide and those who did not. A Kaplan-Meier survival curve was also produced for primary outcome events within a year of surgery. The analyses were performed as in the GALA trial, with logistic regression and P-values presented from the change in log-likelihood on entering the interaction between the subgroup effect and the treatment effect into the model. They were performed using SAS version 9.2 [SAS Institute Inc., Cary, NC, USA].
Results
One thousand seven hundred and seventy-three patients received GA: of these, 671 definitely received nitrous oxide, 944 definitely did not, and for 158, it was unknown. Because this was a non-randomized comparison, it is not surprising that the two groups of interest (definitely vs definitely not receiving nitrous oxide) were not well balanced.
Patients who received nitrous oxide were more likely to have had volatile, rather than i.v. anaesthesia, neuromuscular block and more likely to have received premedication (Table 1) . Patients who received nitrous oxide were also more likely to have had peripheral vascular disease, coronary artery disease, and atrial fibrillation, but also to be ASA category I or II rather than III or IV (Table 2 ) and be younger (Table 2) . Thus, it is likely that patients receiving nitrous oxide were at higher risk of vascular events after operation than in the no nitrous oxide group. 13 14 Patients who received nitrous oxide were also more likely to have a pre-existing infarct on the side of the brain that was being operated on, but the carotid stenosis was less severe; and they were less likely to be on aspirin, clopidogrel, dipyridamole, and warfarin (Table 2) . Finally, intraoperatively, patients in the nitrous oxide group were less likely to have had their arterial pressure manipulated upwards (Table 3) . Overall, there were 35 primary outcome events in the 671 patients receiving nitrous oxide (5.2%) compared with 44 out of the 944 (4.7%) ( 
Discussion
Because GALA was a pragmatic large international multicentre trial, the choice of the GA technique was left to the discretion of individual clinicians in each centre. The choice or otherwise of nitrous oxide would have been part of a package of anaesthetic care that involved other agents including opioids, neuromuscular blocking agents, volatile or i.v. anaesthetic agents, varying oxygen concentrations, and the use of other drugs with cardiovascular effects. Not surprisingly, patients who received nitrous oxide were rather different to those who did not. However, given the greater prevalence of vascular risk factors in the nitrous oxide group and the lack of any definite effect on the primary outcome or any other measure, particularly after statistical adjustment to account for the baseline differences, these data do not suggest any clinically meaningful adverse effects of nitrous oxide on vascular outcomes. The nonsignificant increase in the number of fatal strokes in the nitrous oxide group may be explained by the increased vascular risk inherent in the nitrous oxide group, operation on the side of an existing infarct, nitrous oxide exacerbating an evolving ischaemic injury, or it may simply be due to chance and inadequate adjustment for the imbalances at baseline. Indeed, we must be cautious with the interpretation of our findings because a serious limitation of secondary analyses focusing on non-randomized comparisons within an RCT is that groups are often imbalanced. However, the adjustment for the imbalanced variables did not increase the risk of harm on our primary outcome measure.
With the exception of the secondary analysis of the Intraoperative Hypothermia in Aneurysm Surgery Trial, 5 most previous work has focused on whether there is an increased perioperative risk of myocardial, rather than cerebral ischaemia. With only five myocardial infarctions, our analysis was underpowered to look at myocardial infarction as an independent outcome. At the time we set up the GALA trial, routine troponin analysis was not widespread so it was not adopted for the study, limiting our diagnosis of myocardial infarction to traditional history, clinical examination, and ECG analysis. Therefore, we cannot comment on the association between nitrous oxide exposure and myocardial ischaemia, or indeed silent infarction.
Our postoperative events were predominantly strokes. There was no effect on their overall incidence, although there was a non-significant increase in the unadjusted risk of fatal stroke. Our data potentially contrast with the similarly non-randomized analysis of the Intraoperative Hypothermia in Aneurysm Surgery Trial 5 group that showed a significant increase in delayed ischaemic neurological deficits with nitrous oxide exposure. The difference may be attributable to differing methods of defining the ischaemic events as we do not have data on delayed ischaemic neurological deficits other than stroke. However, we should emphasize that the Intraoperative Hypothermia in Aneurysm Surgery Trial 5 group also did not find a difference in longterm outcomes. Alternatively, this may be attributable to differing mechanisms of cerebral ischaemia. After carotid surgery, ischaemic events are typically thromboembolic, whereas during intracerebral surgery, vasospasm or brain retraction is a more likely cause. Indeed, our data are entirely from patients undergoing carotid surgery and so may not be generalizable to other surgical procedures where nitrous oxide may exert a greater impact. Carotid surgery is of relatively short duration (a mean procedure time of 95 min in the GALA trial) that could further limit any effects of exposure to nitrous oxide that occur in a time-dependent manner. 6 After 90 min of exposure to nitrous oxide, methionine synthase activity has approximately halved; 6 15 however, it may be that a longer exposure is required for any detrimental effect to be observed. It may be that particular groups of patients are vulnerable to nitrous oxide, for example, those malnourished or deficient in cobalamin or folate. 6 Indeed, a recent meta-analysis has suggested that homocysteine-lowering therapy may Number of patients at risk:
The Kaplan -Meier curve for the primary outcome (mortality, stroke, and myocardial infarction event-free) survival 1 yr after carotid endarterectomy. The log-rank test showed no difference in event-free survival at 1 yr between the two groups (P¼0.21).
reduce the risk of stroke in areas where folate deficiency is high, such as Asia. 16 It may be that nitrous oxide exposure in these populations may lead to a particularly raised homocysteine and exacerbations of ischaemia; in turn, this may explain some of the results of the Evaluation of Nitrous Oxide In the Gas Mixture for Anaesthesia (ENIGMA) trial as it was heavily weighted with patients from Asia. 2 Furthermore, certain methylenetetrahydrofolate reductase genotypes [677C.T (rs1801133) or 1298A.C (rs1801131)] incur greater nitrous oxide-induced increases in homocysteine levels than those with wild-type alleles, and thus, these patients may be at greater perioperative risk from exposure to nitrous oxide. 6 17 Future studies should investigate these subgroups of patients. Nonetheless, the lack of effect on the primary outcome in GALA, despite increased vascular risk factors in the nitrous oxide group, adds weight to notion that there is no difference between GA in vascular outcome with or without nitrous oxide. It is possible that our subgroup analysis lacked power to detect a difference between nitrous oxide treatment or not. However, we have not conducted a post hoc power analysis as it is much more informative to look at the CIs around the effect estimates that are observed. 18 19 Indeed, we have discussed the need for future studies to look for vulnerable subgroups of patients as, consistent with the wide confidence limits, there may be patients who are vulnerable to nitrous oxide exposure.
In conclusion, our data from a trial of carotid surgery do not lend support to reports of small RCTs and secondary analyses of other trials that nitrous oxide increases the risk of adverse perioperative vascular events.
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